Skip to main content

HLRCC Foundation

Contact & Join

Staying Ahead of HLRCC: A Head-to-Toe Guide to Screening and Follow-Up

From the HLRCC Foundation

Living with HLRCC means having a plan. The good news is that expert guidelines lay out a clear one, and each part of it aims to find problems early, when they are easier to treat. This guide walks through the whole plan: kidneys, skin, and uterus, plus what it means for your family. At the end you’ll find a list of questions to bring to your next appointment.

A quick refresher: what HLRCC is

HLRCC (hereditary leiomyomatosis and renal cell cancer, also called FH tumor predisposition syndrome) is caused by an inherited change in the FH gene [3]. It can cause noncancerous smooth-muscle growths called leiomyomas in the skin and, in women, in the uterus (fibroids). It also raises the risk of kidney cancer [3][6].

A note on test results: a genetic test that finds a pathogenic (disease-causing) or likely pathogenic FH variant confirms HLRCC [3]. A variant of uncertain significance (VUS) is different. A VUS on its own does not confirm or rule out HLRCC [3]. Experts recommend having a VUS result reviewed by a cancer genetics specialist, ideally at a center with HLRCC experience [4].

Kidneys: yearly MRI, and acting quickly if something is found

What is the risk? About 15 in 100 people with HLRCC develop kidney cancer; most do not [1][6]. Studies have given different numbers, and experts are still refining them [4]. Kidney cancer at a young age is rare: about 1 to 2 in 100 people with HLRCC develop it before age 20 [1][2].

Screening. Experts recommend a dedicated kidney MRI once a year, because HLRCC kidney tumors can be aggressive even when small [1][2][4]. MRI is preferred because it avoids radiation over a lifetime of scans, and ultrasound alone can miss small tumors [1][2][4]. The 2014 international consensus and NCCN’s patient guidelines suggest starting in childhood, between ages 8 and 10 [1][5], and GeneReviews’ summary says from age 8 [3]. The newest pediatric consensus, from a 2023 American Association for Cancer Research (AACR) workshop, recommends starting at around age 10 [2].

We cover the yearly MRI in depth, including contrast, children’s start ages, and tips for scan day, in our article Your Yearly Kidney MRI: Why Screening Matters So Much in HLRCC.

Screening is not the same as “watch and wait.” These two ideas can get mixed up:

  • Screening (also called surveillance) means regular scans in people who have no tumor, to catch one early.
  • Active surveillance (“watch and wait”) means a tumor has already been found, and doctors keep scanning it rather than removing it right away.

In some other inherited kidney cancer conditions, including von Hippel-Lindau disease, hereditary papillary renal carcinoma, and Birt-Hogg-Dubé syndrome, small kidney tumors are often watched and removed once the largest reaches about 3 cm (just over an inch) [1]. HLRCC is the exception. Because HLRCC kidney tumors can spread even when small, experts do not recommend active surveillance for them [1][5]. Instead, they recommend prompt surgery with wide margins (removing some healthy tissue around the tumor), whatever the tumor’s size [1][2][3]. GeneReviews and NCCN say removing the whole kidney should be considered [3][5]. In some cases, especially for small tumors, surgeons may instead remove part of the kidney with a wide margin [1][3][4]. The surgeon may also remove nearby lymph nodes to check them [1][3][4]. Experts also advise against freezing or heating treatments (cryoablation or radiofrequency ablation) for HLRCC kidney tumors [1][3].

Not every spot on a scan is a tumor. If an MRI shows something unclear, such as a complex cyst, guidelines call for prompt, close follow-up imaging, ideally with the same type of scan so results can be compared [3][4]. Any kidney finding should be reviewed by a urologic surgeon who knows HLRCC [3][4].

Skin: regular checks, and relief for painful bumps

Skin leiomyomas are small bumps, skin-colored to light brown, found mostly on the trunk, arms, and legs [3][6]. They usually appear between the teen years and the 30s, often starting in the 20s, and can grow in size and number with age [3][6]. They may be sensitive to cold or touch, or painful [6].

  • Checks: A dermatologist is the right doctor to examine skin leiomyomas [3][4]. GeneReviews recommends a full skin exam every 1 to 2 years from the time of diagnosis [3]. Experts have not agreed on one schedule, so ask your care team what fits you [4].
  • Treatment: Bumps that don’t cause symptoms usually need no treatment [4]. For painful ones, options include removing a bump, laser or freezing treatments, and medicines for pain [3][4].
  • Watch for change: Tell your doctor if a bump starts growing quickly or changes in other ways [2].

Uterine fibroids: an early, open conversation

Uterine fibroids are common in women with HLRCC. GeneReviews estimates that about 40 to 90 in 100 develop them, though these figures may be high [3]. They are often numerous and large, and they tend to appear earlier than fibroids in the general population [6]. The average age at diagnosis is around 30 [3]. Common symptoms are heavy or irregular periods and pelvic pain [3].

  • Starting early: The pediatric consensus recommends teaching girls with HLRCC, from the teenage years, about symptoms to report, such as changes in periods or pain or fullness in the belly [2].
  • Regular care: The National Cancer Institute’s expert summary suggests a yearly gynecology visit for women with a uterus, with pelvic MRI or ultrasound from time to time [4]. GeneReviews advises seeing a gynecologist for symptoms and for reproductive counseling [3].
  • Planning a family: Fibroids in HLRCC can lead to surgery at a young age [4]. If you hope to have children, ask early about options that keep the uterus, such as removing only the fibroids (myomectomy), and about seeing a fertility specialist [4].
  • If you have surgery: Let your surgeon know you have HLRCC. Experts recommend careful lab examination of removed tissue [3].

Your family: one test can guide many relatives

HLRCC is inherited in an autosomal dominant way: each child of a person with HLRCC has a 50% chance of inheriting the FH variant [3][4]. Meeting with a genetic counselor before and after testing is recommended [4].

Once the variant in your family is known, relatives can be tested for that exact variant [3]. Relatives who carry it can start screening. Relatives who test negative for the family’s variant do not need HLRCC screening [1][4]. For children, testing can be done around the age kidney screening would begin, and families decide the timing together with their care team [1][3].

A few rare FH variants also raise the chance of tumors called pheochromocytoma and paraganglioma. People with those specific variants are offered extra checks, such as blood pressure readings, yearly blood or urine tests, and periodic MRI [2][3]. Your genetics team can tell you whether this applies to your family.

Questions to ask your doctor

Bring this list to your next visit:

  1. Is my FH result pathogenic or likely pathogenic, or is it a VUS? What does that mean for me?
  2. When is my next kidney MRI, and who reads it? Has that radiologist seen HLRCC scans before?
  3. If a kidney tumor is found, which surgeon would I see, and do they treat HLRCC kidney tumors?
  4. How often should I have a full skin exam?
  5. How often should I see a gynecologist, and will I need pelvic imaging?
  6. If I want children, what can I do now to protect my fertility? Should I see a fertility specialist?
  7. Which relatives should be offered testing, and how do I share this news with them?
  8. When should my children be tested, and when should their kidney MRIs start?
  9. Does my family’s variant call for extra checks for pheochromocytoma or paraganglioma?
  10. Should I tell my care team before planning a pregnancy, and do I need a kidney scan first? [5]
  11. Who coordinates all of my HLRCC care, and how do I reach them if something changes between visits?

Looking ahead

Screening plans for HLRCC keep improving as researchers learn more. Experts are calling for international studies to fine-tune the guidelines [3]. The National Cancer Institute’s long-running HLRCC study at the NIH Clinical Center (03-C-0066) is enrolling people with known or suspected HLRCC and eligible relatives [7][8]. Every scan you keep and every conversation you start with your family is a step toward staying ahead of HLRCC.

References

  1. Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomäki K, Tomlinson I, Richard S, Linehan WM. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637-644. doi:10.1007/s10689-014-9735-2. PMID: 25012257. PMCID: PMC4574691.
  2. Michaeli O, Kim SY, Mitchell SG, et al. Update on cancer screening in children with syndromes of bone lesions, hereditary leiomyomatosis and renal cell carcinoma syndrome, and other rare syndromes. Clin Cancer Res. 2025;31(3):457-465. doi:10.1158/1078-0432.CCR-24-2171. PMID: 39601780. PMCID: PMC11790369.
  3. Kamihara J, Schultz KA, Rana HQ. FH Tumor Predisposition Syndrome. In: Adam MP, et al., eds. GeneReviews®. University of Washington, Seattle; 1993-2026. Initial posting July 31, 2006; last comprehensive update May 8, 2025. https://www.ncbi.nlm.nih.gov/books/NBK1252/
  4. PDQ® Cancer Genetics Editorial Board. Hereditary Leiomyomatosis and Renal Cell Cancer (PDQ®)–Health Professional Version. National Cancer Institute. Updated November 6, 2024. https://www.cancer.gov/publications/pdq/information-summaries/genetics/hlrcc-syndrome-hp-pdq
  5. National Comprehensive Cancer Network. NCCN Guidelines for Patients®: Kidney Cancer, 2026 (based on NCCN Guidelines® for Kidney Cancer, Version 1.2026, July 24, 2025), chapter 7, “Hereditary RCC.” https://www.nccn.org/patients/guidelines/content/PDF/kidney-patient.pdf
  6. MedlinePlus Genetics. Hereditary leiomyomatosis and renal cell cancer. National Library of Medicine. Last updated February 1, 2018. https://medlineplus.gov/genetics/condition/hereditary-leiomyomatosis-and-renal-cell-cancer/
  7. National Cancer Institute, Center for Cancer Research. Urologic Oncology Branch. https://ccr.cancer.gov/urologic-oncology-branch
  8. ClinicalTrials.gov. NCT00050752: Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer. Status: Recruiting (last update posted November 10, 2026). https://clinicaltrials.gov/study/NCT00050752

Leave a Reply

Your email address will not be published. Required fields are marked *

This is a staging enviroment